GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma
    Future Medicine Ltd ; 2021
    In:  Future Oncology Vol. 17, No. 31 ( 2021-11), p. 4081-4089
    Details
    In: Future Oncology, Future Medicine Ltd, Vol. 17, No. 31 ( 2021-11), p. 4081-4089
    Abstract: Lay abstract Esophageal cancer is a challenging disease that seriously threatens patients’ health and life. Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer. Most patients who have inoperable stage II–IV ESCC are currently treated with a sequential combination of chemotherapy and radiation therapy, with the hopes of increasing the positive effects seen from either therapy alone. Immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have shown encouraging results in patients with ESCC, but it is not known if combining checkpoint inhibitors with simultaneous chemotherapy and radiation therapy will provide additional benefits. The safety and efficacy of tislelizumab, an anti-PD-1 antibody specifically engineered to limit potential resistance to anti-PD-1 therapy, is being investigated in combination with simultaneous chemotherapy and radiation therapy in patients with inoperable stage II–IV ESCC in an actively enrolling clinical trial, RATIONALE 311 (NCT03957590). Our trial in progress article explains the reason RATIONALE 311 was started and provides important enrollment information for doctors. Clinical trial registration: NCT03957590 (ClinicalTrials.gov)
    Type of Medium: Online Resource
    ISSN: 1479-6694 , 1744-8301
    URL: Article
    DOI: 10.2217/fon-2021-0632
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial
    Frontiers Media SA ; 2020
    In:  Frontiers in Oncology Vol. 10 ( 2020-8-28)
    Details
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 10 ( 2020-8-28)
    Type of Medium: Online Resource
    ISSN: 2234-943X
    URL: Article
    DOI: 10.3389/fonc.2020.01499
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2020
    detail.hit.zdb_id: 2649216-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma : A Randomized Clinical Trial
    American Medical Association (AMA) ; 2023
    In:  JAMA Network Open Vol. 6, No. 5 ( 2023-05-17), p. e2312625-
    Details
    In: JAMA Network Open, American Medical Association (AMA), Vol. 6, No. 5 ( 2023-05-17), p. e2312625-
    Abstract: Double-agent intravenous chemotherapy concurrent with radiotherapy is the standard of care for patients with inoperable esophageal cancer. However, patients tend to tolerate intravenous chemotherapy less well with age and comorbidities. It is essential to find a better treatment modality that improves survival outcomes without reducing the quality of life. Objective To evaluate the effectiveness of simultaneous integrated boost radiotherapy (SIB-RT) with concurrent and consolidated oral S-1 chemotherapy for patients aged 70 years and older with inoperable esophageal squamous cell carcinoma (ESCC). Design, Setting, and Participants This multicenter, phase III randomized clinical trial was conducted between March 2017 and April 2020 in 10 centers in China. Patients with inoperable, locally advanced, clinical stage II to IV ESCC were enrolled and randomized to receive SIB-RT concurrent with and followed by oral S-1 chemotherapy (CRTCT group) or SIB-RT alone (RT group). Data analysis was completed on March 22, 2022. Interventions In both groups, the planning gross tumor volume was administered with radiation dose of 59.92 Gy and the planning target volume was administered with radiation dose of 50.4 Gy, in 28 fractions each. In the CRTCT group, concurrent S-1 was administered on radiotherapy days, and consolidated S-1 was administered at 4 to 8 weeks after SIB-RT. Main Outcomes and Measures The primary end point was overall survival (OS) of the intent-to-treat population. Secondary end points were progression-free survival (PFS) and toxicity profile. Results A total of 330 patients (median [IQR] age, 75.5 [72-7 9] years; 220 [66.7%] male patients) were included, with 146 patients randomized to the RT group and 184 randomized to the CRTCT group. A total of 107 patients (73.3%) in the RT group and 121 patients (67.9%) in the CRTCT group were clinically diagnosed with stage III to IV disease. At the time of analysis of the 330 patients in the intent-to treat-population (March 22, 2022), OS was improved in the CRTCT group compared with the RT group at 1 year (72.2% vs 62.3%) and 3 years (46.2% vs 33.9%; log-rank P  = .02). PFS was similarly improved in the CRTCT group compared with the RT group at 1 year (60.8% vs 49.3%) and 3 years (37.3% vs 27.9%; log-rank P  = .04). There was no significant difference in the incidence of treatment-related toxic effects higher than grade 3 between the 2 groups. Grade 5 toxic effects occurred in each group, including 1 patient who experienced myelosuppression and 4 patients with pneumonitis in the RT group and 3 patients with pneumonitis and 2 patients with fever in the CRTCT group. Conclusions and Relevance These findings suggest that oral S-1 chemotherapy administered with SIB-RT should be considered as an alternative treatment option for patients aged 70 years and older with inoperable ESCC, since it improved survival outcomes without additional treatment-related toxic effects compared with SIB-RT alone. Trial Registration ClinicalTrials.gov Identifier: NCT02979691
    Type of Medium: Online Resource
    ISSN: 2574-3805
    URL: Article
    DOI: 10.1001/jamanetworkopen.2023.12625
    Language: English
    Publisher: American Medical Association (AMA)
    Publication Date: 2023
    detail.hit.zdb_id: 2931249-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    DataSheet_1.docx
    Frontiers Media SA ; 2022
    In:  Frontiers in Immunology Vol. 13 ( 2022-6-20)
    Details
    In: Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-6-20)
    Abstract: Whilst survival benefits of thoracic radiotherapy (TRT) followed by immune checkpoint inhibitor (ICI) have been reported in patients with lung cancer, the potential high risk of treatment-related pneumonitis remains a concern. Asians may be more sensitive to lung toxicity than other races. This retrospective study intended to provide a comprehensive pneumonitis profile of TRT followed by ICI and investigate the risk factors from a Chinese cohort of lung cancer. Methods and Materials From January 2016 to July 2021, 196 patients with lung cancer who received TRT prior to ICI were retrospectively analyzed. Treatment-related pneumonitis, including checkpoint inhibitor pneumonitis (CIP), radiation pneumonitis (RP), and radiation recall pneumonitis (RRP), were recorded and graded through medical records and chest computed tomography. Characteristics predictive of pneumonitis were assessed using logistic regression models, and the receiver operating characteristic analyses were performed to identify optimal cut points for quantitative variables. Results With a median follow-up of 18 months, a total of 108 patients (55.1%) developed treatment-related pneumonitis during ICI therapy, with an incidence of 25.5% for grade 2 or higher (G2+) and 4.1% for G3+. The overall rates of CIP, RP and RRP were 8.2% (n=16), 46.9% (n=92) and 7.1% (n=14), respectively. With a total mortality rate of 1.5%, vast majority of the patients recovered from pneumonitis or remained stable. No patients died of RRP. Half of the patients with G2+ RP who withheld ICI therapy restarted ICI safely after resolution of RP. The history of chronic pulmonary diseases ( P =0.05), mean lung dose (MLD, P =0.038), percent volume of lung receiving ≥5 Gy (V5, P =0.012) and percent volume of lung receiving ≥20 Gy (V20, P =0.030) predicted the occurrence of RRP in univariate analyses. Interval between TRT and ICI less than 3 months was an independent predictor for G2+ treatment-related pneumonitis in a multivariate model (Odds ratio OR=2.787, P =0.004). Conclusions Treatment-related pneumonitis, especially RRP, is acceptable and manageable in the setting of TRT followed by ICI in this Asian population. Dosimetric parameters MLD, V5 and V20 may improve the predictions of RRP in clinical practice.
    Type of Medium: Online Resource
    ISSN: 1664-3224
    URL: Article
    URL: Article
    DOI: 10.3389/fimmu.2022.918787
    DOI: 10.3389/fimmu.2022.918787.s001
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2022
    detail.hit.zdb_id: 2606827-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    A phase III trial in progress comparing tislelizumab plus concurrent chemoradiotherapy (cCRT) with placebo plus cCRT in patients with localized esophageal squamous cell carcinoma (ESCC).
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  Journal of Clinical Oncology Vol. 38, No. 4_suppl ( 2020-02-01), p. TPS475-TPS475
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, No. 4_suppl ( 2020-02-01), p. TPS475-TPS475
    Abstract: TPS475 Background: In China, esophageal cancer (EC) ranks as the eigth most common cancer and the sixth most common cause of cancer related death. The predominant histological subtype of EC is ESCC. At first diagnosis, more than half of patients (pts) with ESCC are unfit for surgery. An alternative to surgery is cCRT; however, many pts experience local failure or distant metastasis after cCRT. As such, innovative therapies are needed. Tislelizumab, an investigational humanized monoclonal antibody with high affinity and specificity for PD-1, was engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. In previous studies, tislelizumab, as a monotherapy and in combination with chemotherapy, was generally well tolerated and had antitumor activity in pts with ESCC. Methods: This phase 3, randomized, double-blind, placebo-controlled study (NCT03957590) is designed to compare the efficacy of tislelizumab versus placebo in combination with cCRT. Patients with histologically confirmed localized ESCC for whom cCRT is suitable and surgery is unsuitable/declined are being enrolled. Approximately 316 Chinese pts will be randomized 1:1 to receive tislelizumab (200 mg IV Q3W) or placebo (IV Q3W) in combination with cisplatin (25 mg/m 2 IV on Days 1-3 of each 3-week cycle) plus paclitaxel (135 mg/m 2 IV Q3W) and radiotherapy at a total dose of 50.4 Gy. An Independent Data Monitoring Committee will be established to assess the safety/tolerability of tislelizumab plus cCRT in the first 20 enrolled pts; monitoring across the study will occur at regular intervals thereafter. Progression-free survival (PFS), assessed by a Blinded Independent Review Committee per RECIST v1.1, is the primary endpoint. Secondary efficacy endpoints include overall response rate, duration of response, and overall survival. Incidence and severity of adverse events (CTCAE V5.0) and HRQoL are additional secondary endpoints. Exploratory endpoints include PFS rate at Years 1 and 2, pharmacokinetic profile, and predictive biomarker analyses. Clinical trial information: NCT03957590.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2020.38.4_suppl.TPS475
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter, Open Label, Randomized Phase III Clinical Trial
    Elsevier BV ; 2022
    In:  SSRN Electronic Journal
    Details
    In: SSRN Electronic Journal, Elsevier BV
    Type of Medium: Online Resource
    ISSN: 1556-5068
    URL: Article
    DOI: 10.2139/ssrn.4094835
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Charge Regulation on Hybrid Nanosheet Stereoassembly via Interfacial PO Coupling Enables Efficient Overall Water Splitting
    Wiley ; 2023
    In:  Advanced Functional Materials Vol. 33, No. 27 ( 2023-07)
    Details
    In: Advanced Functional Materials, Wiley, Vol. 33, No. 27 ( 2023-07)
    Abstract: Precise regulation on interfacial electronic coupling is essential to achieve efficient catalysts with tailored electrocatalytic behaviors but remains challenging. Herein, a straightforward topochemical strategy is presented to realize Co‐based heterostructured nanofiber stereoassembled with PO coupled nanosheet (CoHF/PO). By constructing well‐defined metal oxide/phosphide interface, prominent electron redistribution can be established via interfacial PO coupling, which is strongly correlated with the catalytic activities. Density functional theory calculations indicate that the rational interface engineering renders accelerated charge transfer and more importantly, optimized surface adsorption/desorption behaviors, contributing to boosted kinetics for both hydrogen evolution reaction and oxygen evolution reaction. Particularly, CoHF/PO featuring promoted intrinsic activity and accessible active sites exhibits intriguing activity and stability at higher current densities in alkaline media, surpassing commercial Pt/C and Ir/C. This study is expected to demonstrate noteworthy promise of covalent coupling toward modulated electronic environment and interface chemistry for electrocatalytic applications and beyond.
    Type of Medium: Online Resource
    ISSN: 1616-301X , 1616-3028
    URL: Issue
    URL: Article
    DOI: 10.1002/adfm.v33.27
    DOI: 10.1002/adfm.202214075
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2029061-5
    detail.hit.zdb_id: 2039420-2
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Rescue Work and Progress of Analog Seismograms in China
    Seismological Society of America (SSA) ; 2020
    In:  Seismological Research Letters Vol. 91, No. 5 ( 2020-09-01), p. 2704-2718
    Details
    In: Seismological Research Letters, Seismological Society of America (SSA), Vol. 91, No. 5 ( 2020-09-01), p. 2704-2718
    Abstract: Rescue work involving scanning and digitization research on historical analog seismograms nationwide in China was launched in 2017. A series of results have been accomplished. There are more than 13 million analog seismic records existing in China, and about 3 million of them were scanned by December 2019. The Second Monitoring and Application Center of China Earthquake Administration completed the phased construction of the “China Analog Seismic Record Rescue Project” in 2019, which has received a great deal of funding support. Most of the analog seismograms and geophysical records in China will be scanned in the following decade, the corresponding stations and instrument parameters will be also collected during this project to provide retrieval and download service. This article first introduces the survey statistics about scanning and digitalization progress of analog seismic records in China. Second, a management and service system for the storage and query of large scale of seismograms has been established based on distributed database and search engine. Finally, future prospects of the rescue work of analog seismograms are mentioned.
    Type of Medium: Online Resource
    ISSN: 0895-0695 , 1938-2057
    URL: Article
    DOI: 10.1785/0220200077
    Language: English
    Publisher: Seismological Society of America (SSA)
    Publication Date: 2020
    detail.hit.zdb_id: 2403376-5
    SSG: 16,13
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Boosting Charge Transfer Via Heterostructure Engineering of Ti 2 CT x /Na 2 Ti 3 O 7 Nanobelts Array for Superior Sodium Storage Performance
    Wiley ; 2022
    In:  Small Vol. 18, No. 41 ( 2022-10)
    Details
    In: Small, Wiley, Vol. 18, No. 41 ( 2022-10)
    Abstract: The poor conductivity, inert charge transmission efficiency, and irreversible Na + trapping of Na 2 Ti 3 O 7 result in retardant electrons/ions transportation and deficient sodium‐ion storage efficiency, leading to sluggish reaction kinetics. To address these issues, an urchin‐like Ti 2 CT x /Na 2 Ti 3 O 7 (Ti 2 C/NTO) heterostructure sphere consisting of Ti 2 C/NTO heterostructure nanobelts array is developed via a facile one‐step in situ hydrothermal strategy. The Ti 2 C/NTO heterostructure can obviously decrease Na + diffusion barriers and increase electronic conductivity to improve reaction kinetics due to the built‐in electric field effect and high‐quantity interface region. In addition, the urchin‐like vertically aligned nanobelts can reduce the diffusion distance of electrons and ions, provide favored electrolyte infiltration, adapt large volume expansion, and mitigate the aggregation to maintain structural stability during cycles, further enhancing the reaction kinetics. Furthermore, the Ti 2 C/NTO heterostructure can effectively suppress many unwanted side reactions between reactive surface sites of NTO and electrolyte as well as irreversible trapping of Na + . As a result, systematic electrochemical investigations demonstrate that the Ti 2 C/NTO heterostructure as an anode material for record sodium‐ion storage delivers the highest reversible capacity, the best cycling stability with 0.0065% decay rate for 4500 cycles at 2.0 A g –1 , and excellent rate capability of 172.1 mAh g –1 at 10.0 A g –1 .
    Type of Medium: Online Resource
    ISSN: 1613-6810 , 1613-6829
    URL: Issue
    URL: Article
    DOI: 10.1002/smll.v18.41
    DOI: 10.1002/smll.202203948
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2168935-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Non-Uniform Network Mapping and Localization
    Institute of Electrical and Electronics Engineers (IEEE) ; 2020
    In:  IEEE Access Vol. 8 ( 2020), p. 79708-79715
    Details
    In: IEEE Access, Institute of Electrical and Electronics Engineers (IEEE), Vol. 8 ( 2020), p. 79708-79715
    Type of Medium: Online Resource
    ISSN: 2169-3536
    URL: Article
    DOI: 10.1109/ACCESS.2020.2987104
    Language: Unknown
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date: 2020
    detail.hit.zdb_id: 2687964-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...